The Global Health Challenge of Blood-Borne Diseases in Cancer Patients

Rising Incidence of Hepatitis and HIV

The increase in blood-borne diseases such as hepatitis infections and HIV presents a significant global health challenge. Recently, a team of doctors sought to assess the importance of screening for these infections in cancer patients. Despite initiatives from the World Health Organization (WHO) and other health bodies aimed at early diagnosis and treatment, routine screening for hepatitis and HIV in cancer patients remains largely unimplemented.

Importance of Early Diagnosis in Cancer Patients

Early detection of hepatitis infections is crucial for cancer patients, as cancer treatments can compromise their immune systems, potentially leading to the reactivation of viral hepatitis. Identifying these infections early allows for modifications in treatment protocols and reduces the risk of transmission to others. Therefore, screening for hepatitis infections and HIV in cancer patients is essential.

Study Overview and Findings

A study conducted by the SWOG Cancer Research Network, published in JAMA Oncology, focused on newly diagnosed cancer patients aged 18 and older. These patients were tested for HBV, HCV, and HIV through straightforward blood tests within 120 days of their cancer diagnosis. Participants completed a questionnaire regarding demographics and potential risk factors for these infections. Among the participants, 60.4% were female, 18.1% identified as Black, and 18.3% were of Hispanic origin. The majority had breast (34.7%), blood/marrow (12.1%), colorectal (11.9%), and lung (11.7%) cancers.

Prevalence of Hepatitis and HIV in the Patient Cohort

The study revealed that the rates of hepatitis infections in the patient population were comparable to those in the general U.S. population. Among the patients tested, 6.5% had a Hepatitis B infection, 0.6% had chronic Hepatitis B, and 2.4% had Hepatitis C. HIV was diagnosed in 1.1% of the patients. Newly diagnosed cases included eight patients (42.1%) with Hepatitis B, two (5.9%) with HIV, and 22 (31%) with Hepatitis C. These findings underscore the prevalence of undiagnosed hepatitis infections among cancer patients, particularly those with liver cancer. Notably, many participants exhibited no identifiable risk factors for these infections.

Impact on Cancer Treatment Protocols

Changes in cancer treatment protocols were observed in newly diagnosed cases of HIV and hepatitis infections. A significant proportion of patients with chronic Hepatitis B (73.3%) and HIV (66.7%) were initiated on antiviral therapies. Additionally, 58.5% of the infected patients experienced alterations in their cancer treatment regimens within six months, particularly among newly diagnosed individuals. These adjustments were made to prevent complications such as liver failure and kidney disease.

Study Limitations and Future Research Directions

While this study included a diverse group of cancer patients from various geographic, ethnic, and racial backgrounds, it faced certain limitations, such as the absence of a standardized method for detecting Hepatitis B. Future research is necessary to investigate the effects of antiviral medications on this patient population.

Conclusion: The Need for Universal Screening

The findings of this study highlight the critical need for hepatitis infection testing in cancer patients. Modern cancer therapies can impact the immune system, increasing the risk of hepatitis reactivation. Researcher Joseph M. Unger emphasized, “From a public health perspective, chronic hepatitis B and hepatitis C are a significant challenge, since these infections affect millions of Americans, including many patients with cancer. Testing cancer patients for these diseases could catch a lot of undiagnosed cases and help modify their cancer care to improve outcomes.”

Implementing universal screening for hepatitis infections in cancer patients is imperative. Although it may induce anxiety or result in additional treatment burdens, early detection can prevent flare-ups and adverse outcomes during cancer treatment.

References

Ramsey S, Unger J, Baker L, Little R, Loomba R, Hwang J et al. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncology. 2019.
Many hepatitis infections go undiagnosed in cancer patients [Internet]. EurekAlert!. 2019 [cited 7 February 2019]. Available from: https://www.eurekalert.org/pub_releases/2019-01/smhi011619.php